Melatonin Dosage and Timing Recommendations
Critical Distinction: Insomnia vs. Circadian Rhythm Disorders
Melatonin should NOT be used for chronic insomnia in adults, but IS recommended for delayed sleep-wake phase disorder (DSWPD) and other circadian rhythm disorders. This is the most important clinical distinction when prescribing melatonin 1.
For Chronic Insomnia (Primary Sleep Disorder)
Adults
The American Academy of Sleep Medicine recommends AGAINST using melatonin for chronic insomnia in adults 1. The 2017 guideline explicitly states clinicians should not use melatonin (studied at 2 mg doses) as treatment for sleep onset or sleep maintenance insomnia versus no treatment. Instead, consider FDA-approved alternatives like eszopiclone, zolpidem, or ramelteon (a melatonin receptor agonist, not melatonin itself).
For Delayed Sleep-Wake Phase Disorder (DSWPD)
Adults with DSWPD
Use 5 mg of melatonin taken between 19:00-21:00 (7-9 PM) for at least 28 days 2. This timing is 1.5-3 hours before desired bedtime, not 30 minutes as commonly practiced. The evidence quality is LOW, but clinical acceptance is high given the favorable safety profile.
Key timing principle: Melatonin works by phase-advancing the circadian rhythm, not as a sedative-hypnotic. Earlier administration (3 hours before bedtime) appears more effective than the commonly used 30-minute window 3.
Children/Adolescents with DSWPD (No Comorbidities)
Use 0.15 mg/kg taken 1.5-2.0 hours before habitual bedtime 2. This translates to approximately:
- Mean dose of 4.4 mg for children ages 6-12 years
- Evidence quality: MODERATE
Important caveat: Long-term safety data in pediatric populations are lacking. Obtain informed consent from caregivers regarding uncertain long-term effects on development.
Children/Adolescents with DSWPD and Psychiatric Comorbidities (e.g., ADHD)
Use fast-release melatonin 3-5 mg at 18:00-19:00 (6-7 PM) 2. Weight-based dosing:
- 3 mg if <40 kg
- 5 mg if ≥40 kg
- Evidence quality: LOW
This earlier timing (18:00-19:00) for psychiatric comorbidities differs from the general pediatric recommendation, reflecting the need for greater circadian phase advancement in this population.
For Jet Lag and Shift Work Sleep Disorder
The provided guidelines focus on DSWPD rather than jet lag or shift work. However, research evidence suggests:
For shift work disorder: Melatonin 1-10 mg has shown effectiveness in reducing daytime sleepiness, decreasing sleep onset latency, and improving total sleep time 4. The wide dosage range reflects lack of standardization, but 4 mg appears optimal based on dose-response analysis 3.
Timing for shift workers: Administer 3 hours before the desired sleep episode, not immediately before attempting sleep 3, 5.
Optimal Dosing Principles Across Indications
Based on the most recent dose-response meta-analysis 3:
- Dose: Melatonin's sleep-promoting effects peak at 4 mg/day, not the commonly used 2 mg
- Timing: Administer 3 hours before desired bedtime, not 30 minutes
- Formulation: Fast-release preferred for circadian phase shifting
Common pitfall: Most clinicians prescribe 2 mg taken 30 minutes before bed—this is suboptimal. The evidence supports higher doses (4-5 mg) taken much earlier (2-3 hours before bedtime) for circadian disorders.
Safety Considerations
- Short-term adverse effects are minimal and resolve upon discontinuation 6, 7
- Long-term safety data (>6 months) are limited, particularly in children 2
- No evidence of dependence even at high doses 6
- Critical regulatory issue: In the U.S., melatonin is an unregulated dietary supplement with significant variability between labeled and actual content 5, 7
Clinical Algorithm
Step 1: Determine if the patient has:
- Chronic insomnia → Do NOT use melatonin in adults; consider FDA-approved alternatives 1
- Circadian rhythm disorder (DSWPD) → Proceed to Step 2
Step 2: Select dose based on age and comorbidities:
- Adults: 5 mg at 19:00-21:00 2
- Children without comorbidities: 0.15 mg/kg 1.5-2 hours before bedtime 2
- Children with psychiatric comorbidities: 3-5 mg (weight-based) at 18:00-19:00 2
Step 3: Duration
Step 4: Reassess if no response after 4 weeks; consider alternative diagnoses or treatments.